文献速递流行病学与生物统计

周期性筛查性盆腔检查:美国预防服务工作组证据报告与系统综述

Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2017-01-01

本系统综述为美国预防服务工作组(USPSTF)评估无症状女性筛查性盆腔检查的健康获益、准确性和危害。检索至2016年1月13日的文献,纳入9项研究共27630例患者;未发现试验评估盆腔检查对全因死亡率、癌症及疾病特异性发病率与死亡率或生活质量的影响,仅有限证据涉及卵巢癌、细菌性阴道病、滴虫病和生殖器疱疹的诊断准确性及危害。

要点

  • 无试验评估筛查性盆腔检查对全因死亡率、癌症或疾病特异性发病率与死亡率或生活质量的影响。
  • 卵巢癌筛查研究中阳性预测值范围为0%-3.6%,阴性预测值范围≥99%,准确性估计缺乏精确性。
  • 卵巢癌筛查异常后1年内手术率范围为5%-36%,最大研究报告手术率11%、并发症率1%。

核心结论

  • 未识别出直接证据支持盆腔检查作为一次性或周期性筛查试验的总体获益与危害。
  • 关于无症状初级保健人群中常规筛查性盆腔检查的诊断准确性和危害,证据有限。

研究设计与样本

  • 为USPSTF进行的系统综述,检索MEDLINE、PubMed和Cochrane对照试验中心注册库中截至2016年1月13日发表的英文研究,监测至2016年8月3日。
  • 两名评价者独立筛选摘要和研究,检索获得8678条唯一引文,审查316篇全文,最终9项研究共27630例患者符合纳入标准。
  • 两名评价者使用USPSTF标准评定研究质量。

主要发现

  • 无试验评估盆腔检查在降低全因死亡率、降低癌症及疾病特异性发病率与死亡率或改善生活质量方面的有效性。
  • 8项研究报告筛查性盆腔检查的诊断准确性:卵巢癌4项研究(n=26432)、细菌性阴道病2项研究(n=930)、滴虫病1项研究(n=779)、生殖器疱疹1项研究(n=779)。
  • 4项卵巢癌筛查研究中,卵巢癌低患病率一致导致低阳性预测值(PPV范围0%-3.6%)和假阳性率,准确性估计缺乏精确性(灵敏度范围0%-100%;特异度范围91%-99%;阴性预测值[NPV]范围≥99%)。
  • 细菌性阴道病、滴虫病和生殖器疱疹的每项诊断准确性研究均在高患病率人群中进行,其中有相当比例的有症状患者,并报告了个体体格检查发现的准确性特征。
  • 卵巢癌筛查性盆腔检查异常后1年内手术率范围为5%-36%,最大研究报告筛查性盆腔检查异常发现后1年内手术率11%、并发症率1%。

关键数值与推荐

  • 细菌性阴道病均质分泌物:灵敏度范围69%-79%;特异度范围54%-97%;PPV范围52%-95%;NPV范围79%-80%。
  • 单纯疱疹病毒外阴溃疡:灵敏度20%;特异度98%;PPV 88%;NPV 57%。
  • 滴虫病草莓斑阴道炎:灵敏度2%;特异度100%;PPV 100%;NPV 85%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未识别出直接证据支持盆腔检查作为一次性或周期性筛查试验的总体获益与危害。
  • 关于无症状初级保健人群中常规筛查性盆腔检查的诊断准确性和危害,证据有限。
  • 卵巢癌筛查研究中准确性估计缺乏精确性(灵敏度范围0%-100%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recent changes in the periodicity of cervical cancer screening have led to questions about the role of screening pelvic examinations among asymptomatic women. OBJECTIVE: To systematically review literature on health benefits, accuracy, and harms of the screening pelvic examination for gynecologic conditions for the US Preventive Services Task Force (USPSTF). DATA SOURCES: MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials for relevant English-language studies published through January 13, 2016, with surveillance through August 3, 2016. STUDY SELECTION: Two reviewers independently screened abstracts and studies. The search yielded 8678 unique citations; 316 full-text articles were reviewed, and 9 studies including 27 630 patients met inclusion criteria. DATA EXTRACTION AND SYNTHESIS: Two reviewers rated study quality using USPSTF criteria. MAIN OUTCOMES AND MEASURES: Morbidity; mortality; diagnostic accuracy for any gynecologic cancer or condition except cervical cancer, gonorrhea, and chlamydia, which are covered by other USPSTF screening recommendations; harms (false-positive rates, false-negative rates, surgery rates). RESULTS: No trials examined the effectiveness of the pelvic examination in reducing all-cause mortality, reducing cancer- and disease-specific morbidity and mortality, or improving quality of life. Eight studies reported accuracy for the screening pelvic examination: ovarian cancer (4 studies; n = 26 432), bacterial vaginosis (2 studies; n = 930), trichomoniasis (1 study; n = 779), and genital herpes (1 study; n = 779). In the 4 ovarian cancer screening studies, low prevalence of ovarian cancer consistently resulted in low positive predictive values (PPVs) and false-positive rates, with a lack of precision in accuracy estimates (sensitivity range, 0%-100%; specificity range, 91%-99%; PPV range, 0%-3.6%; negative predictive value [NPV] range, ≥99%). Each diagnostic accuracy study for bacterial vaginosis, trichomoniasis, and genital herpes was performed in a high-prevalence population with substantial proportions of symptomatic patients and reported accuracy characteristics for individual physical examination findings (bacterial vaginosis, homogeneous discharge: sensitivity range, 69%-79%; specificity range, 54%-97%; PPV range, 52%-95%; NPV range, 79%-80%; herpes simplex virus, vulvar ulcerations: sensitivity, 20%; specificity, 98%; PPV, 88%; NPV, 57%; trichomoniasis, colpitis macularis: sensitivity, 2%; specificity, 100%; PPV, 100%; NPV, 85%). Surgery rates resulting from an abnormal screening pelvic examination for ovarian cancer ranged from 5% to 36% at 1 year, with the largest study reporting an 11% surgery rate and 1% complication rate within 1 year of a screening pelvic examination with abnormal findings. CONCLUSIONS AND RELEVANCE: No direct evidence was identified for overall benefits and harms of the pelvic examination as a 1-time or periodic screening test. Limited evidence was identified regarding the diagnostic accuracy and harms of routine screening pelvic examinations in asymptomatic primary care populations.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Guirguis-Blake JM, Henderson JT, Perdue LA, et al. Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017. PMID: 28267861. doi:10.1001/jama.2016.12819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。